Journal of Thyroid Research / 2012 / Article / Tab 1

Review Article

Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

Table 1

Inhibitory concentration 50 (IC50) of the major pharmaceutical compounds in clinical development for the treatment of thyroid cancer segregated with respect to the kinase activity required to inhibit different molecular targets (nmol/L).

Pharmaceutical compoundVEGFR1VEGFR2VEGFR3RETRET/PTCPDGFRβBRAFKITOthers (IC50)

Sorafenib2690204750572568
Motesanib23659848
Axitinib0.10.20.291.221.7
Sunitinib101010100224391–10
Vandetanib40110130100EGFR (500)
Pazopanib1030478474
Lenvatinib (E7080)2245.23539FGFR1 (46)
Cabozantinib (XL-184)0.0354C-MET (1.8)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.